Lv5
1340 积分 2024-09-30 加入
Secular trend in disease burden of leukemia and its subtypes in China from 1990 to 2019 and its projection in 25 years
7个月前
已完结
Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects
7个月前
已完结
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
7个月前
已完结
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia
7个月前
已完结
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia
8个月前
已完结
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
8个月前
已完结
Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
8个月前
已完结
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
8个月前
已完结
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial
8个月前
已完结
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results
8个月前
已完结
皖公网安备34019202002308
